SynCardia Systems, LLC, headquartered in Tucson, Arizona, was founded in 2001 and is the sole manufacturer and provider of the world's only clinically proven and commercially approved Total Artificial Heart. In clinical use for more than 35 years, the SynCardia temporary Total Artificial Heart (TAH) is the most widely used and extensively studied Total Artificial Heart in the world. In September 2016, SynCardia was acquired by Versa Capital Management, LLC, a Philadelphia-based private equity investment firm which has provided financial and operational resources.

Property Value
dbo:abstract
  • SynCardia Systems, LLC, headquartered in Tucson, Arizona, was founded in 2001 and is the sole manufacturer and provider of the world's only clinically proven and commercially approved Total Artificial Heart. In clinical use for more than 35 years, the SynCardia temporary Total Artificial Heart (TAH) is the most widely used and extensively studied Total Artificial Heart in the world. In 2004, the FDA approved the SynCardia TAH (formerly known as the "CardioWest temporary Total Artificial Heart”) as a bridge to donor heart transplant in cardiac transplant-eligible candidates at risk of imminent death from end-stage biventricular failure. SynCardia's products include the original 70cc TAH; the newer, smaller 50cc TAH, designed to fit patients of smaller stature, including more women and adolescents; the Companion 2 (C2) Hospital Driver, which provides pneumatic power to the TAH from implant through patient recovery in the hospital; and the Freedom Portable Driver, a smaller, portable pneumatic pump for the TAH that allows stable patients who meet discharge criteria to enjoy life at home while they wait for a matching donor heart. In addition to its approval as a bridge to transplant in the U.S., Canada and Europe, the 70cc TAH is currently undergoing an FDA clinical trial in the U.S. for use as destination therapy in adult patients who are not eligible for transplant. The smaller 50cc TAH is currently approved for use in Europe and Canada and is undergoing an FDA clinical trial in the U.S. as a bridge to transplant for both pediatric and adult patients. In September 2016, SynCardia was acquired by Versa Capital Management, LLC, a Philadelphia-based private equity investment firm which has provided financial and operational resources. A documentary about the SynCardia TAH was released in 2016. A January 2019 report in Europe stated that "there is only one fully artificial heart currently in the market, developed by US-based SynCardia". Also in January, Don Webber was named CEO of SynCardia. (en)
dbo:formerName
  • CardioWest (en)
dbo:headquarter
dbo:product
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-08-31 08:52:01Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 36334243 (xsd:integer)
dbo:wikiPageLength
  • 7343 (xsd:integer)
dbo:wikiPageModified
  • 2019-08-31 08:51:57Z (xsd:date)
dbo:wikiPageOutDegree
  • 17 (xsd:integer)
dbo:wikiPageRevisionID
  • 913315507 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • SynCardia Systems, LLC, headquartered in Tucson, Arizona, was founded in 2001 and is the sole manufacturer and provider of the world's only clinically proven and commercially approved Total Artificial Heart. In clinical use for more than 35 years, the SynCardia temporary Total Artificial Heart (TAH) is the most widely used and extensively studied Total Artificial Heart in the world. In September 2016, SynCardia was acquired by Versa Capital Management, LLC, a Philadelphia-based private equity investment firm which has provided financial and operational resources. (en)
rdfs:label
  • SynCardia Systems (en)
owl:sameAs
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • SynCardia Systems (en)
is foaf:primaryTopic of